Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2026)

Halozyme Therapeutics (HALO) has 11 years of Tax Provisions data on file, last reported at $30.3 million in Q1 2026.

• On a quarterly basis, Tax Provisions rose 17.66% year-over-year to $30.3 million in Q1 2026; TTM through Mar 2026 was $154.5 million, a 29.21% increase from a year earlier, with the FY2025 full-year figure at $150.0 million, up 32.68% from the prior year.
• Tax Provisions for Q1 2026 stood at $30.3 million, down from $40.7 million in the prior quarter.
• Over the last five years, Tax Provisions for HALO reached as high as $43.7 million in Q3 2025 and fell as low as $7.3 million in Q2 2022.
• Historically, Tax Provisions has averaged $23.9 million across 5 years, with a median of $19.9 million in 2023.
• Across the five-year window, Tax Provisions jumped 12531.03% in 2022 and dropped 11.73% in 2023, its largest moves.
• Year by year, Tax Provisions stood at $13.1 million in 2022, then rose by 20.61% to $15.8 million in 2023, then jumped by 160.99% to $41.2 million in 2024, then declined by 1.12% to $40.7 million in 2025, then retreated by 25.68% to $30.3 million in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $30.3 million in Q1 2026, $40.7 million in Q4 2025, and $43.7 million in Q3 2025.